TNFSF11 and prostate carcinoma: Although strong osteoclast targeting therapies, including bisphosphonates [24] and RANKL-targeting denosumab [22,23] are already used to treat patients with bone metastases originating from prostate cancer, drug resistance or intolerance compels the continued search of new treatments.